Mark Soloway
Overview
Explore the profile of Mark Soloway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, et al.
Eur Urol
. 2024 Aug;
86(6):516-527.
PMID: 39183090
Background And Objective: There has been a recent surge in the development of agents for bacillus Calmette-Guérin-unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC). Critical assessment of these agents and practical recommendations...
2.
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, et al.
J Urol
. 2023 Aug;
210(5):770.
PMID: 37622536
No abstract available.
3.
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, et al.
J Urol
. 2023 Aug;
210(5):763-770.
PMID: 37535836
Purpose: We sought to determine if the International Bladder Cancer Group IR-NMIBC (Intermediate-risk Nonmuscle-invasive Bladder Cancer) scoring system can predict the requirement of delayed transurethral resection of bladder tumor in...
4.
Roumiguie M, Kamat A, Bivalacqua T, Lerner S, Kassouf W, Bohle A, et al.
Eur Urol
. 2021 Dec;
82(1):34-46.
PMID: 34955291
Context: A large proportion of patients with non-muscle-invasive bladder cancer (NMIBC) fall in the gap between bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive disease. As multiple therapeutic agents move into this gray...
5.
6.
Mostafid H, Kamat A, Daneshmand S, Palou J, Taylor 3rd J, McKiernan J, et al.
Eur Urol Oncol
. 2020 Jul;
4(1):12-19.
PMID: 32684515
Context: Transurethral resection of bladder tumour (TURBT) for bladder cancer (BC) is an underappreciated common urological procedure. TURBT outcomes are highly variable, and results are dependent on judgement and surgical...
7.
Mostafid H, Babjuk M, Bochner B, Lerner S, Witjes F, Palou J, et al.
Eur Urol
. 2020 Mar;
77(6):669-670.
PMID: 32192815
Transurethral resection of bladder tumour is the initial, most critical step in the management of bladder cancer; as such, this is a call to arms for the urological community to...
8.
Matulay J, Soloway M, Witjes J, Buckley R, Persad R, Lamm D, et al.
BJU Int
. 2020 Jan;
125(4):497-505.
PMID: 31950596
Objective: To provide a contemporary update and recommendations for the diagnosis and management of low-grade non-muscle-invasive bladder cancer (BCa) based on current literature and expert consensus of the International Bladder...
9.
Soloway M, Matulay J, Kamat A
Eur Urol Oncol
. 2019 Oct;
3(1):128-129.
PMID: 31645295
Management of low-grade bladder cancer should focus on minimizing morbidity and costs given the excellent oncologic outcomes.
10.
Joseph J, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, et al.
Bladder Cancer
. 2018 Nov;
4(Suppl 1):S1-S43.
PMID: 30443561
No abstract available.